Prevest Denpro Ltd.
Snapshot View

316.00 -11.25 ▼-3.4%

24 May 2022, 04:01:00 PM
Volume: 7,200

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Medical Equipment/Supplies/Accessories Compare with Industry peers
Website http://www.prevestdenpro.com
Market Cap 377.37 Cr.
Enterprise Value(EV) 380.66 Cr. 2022-03
Financial Indicators
Earnings per share (EPS) 9.64 Trailing Twelve Months Ending 2022-03
Price-Earning Ratio (PE) 32.62 Trailing Twelve Months Ending 2022-03
Industry PE 39.51 Trailing Twelve Months Ending 2022-03
Book Value / Share 47.58 Trailing Twelve Months Ending 2022-03
Price to Book Value 6.61 Calculated using Price: 314.40
Dividend Yield 0.00 Period Ending 2021-03
No. of Shares Subscribed 1.20 Cr. 12,003,000 Shares
FaceValue 10
Company Profile

The company develops, manufacture and market a comprehensive portfolio of dental materials for diagnosing, treating and preventing dental conditions as well as improving the aesthetics of the human smile. The breadth and depth of its product offerings address majority of the dentists’ clinical needs for consumable dental materials. Its product portfolio covers a wide spectrum of materials for endodontics, prosthodontics, orthodontics, periodontics, restorative dentistry, aesthetic dentistry and laboratory consumables. Its products are sold in the regions of Europe, Asia, South America, Middle East and Africa. Further, as per its diversification plans, the company is currently expanding its existing manufacturing unit by setting up another manufacturing facility for manufacturing new line of products that will include hygiene products (sanitizers and disinfectants), oral hygiene products (mouth washes and mouth rinses), oral care products(medicated ointments, gels and creams for dental treatment) and biomaterials (i.e. bone augmentation materials). The proposed facility will be well-equipped with latest machineries.

Business area of the company

The company manufactures and markets a range of dental materials for diagnosing, treating, and preventing dental conditions and improving the aesthetics of the human smile.

Key events and milestones

  • 1999: Incorporation of the Company.
  • 2000: First Manufacturing unit was established at Digiana, Jammu, J&K.
  • 2011: Second Manufacturing unit was established at Samba, J&K.
  • 2014-15: Crossed Turnover of Rs 10 crore.
  • 2016: Won Sushruta award for Best Dental Manufacture by the Indian Dental Association’s.
  • 2016: Received Certificate for ‘Best Enterprise’ in the field of manufacture of dental materials, India by the Socrates Committee, Oxford, UK.
  • 2017: Shifted manufacturing operations from First Manufacturing Unit to Second Manufacturing unit.
  • 2017: Won “Northern Region Export Excellence Award” - Gold Trophy for outstanding export performance in the category of top exporter J&K - SME by FIEO (2017).
  • 2019-20: Crossed Turnover of Rs 20 crore.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-3.44%
1 Week
-12.72%
1 Month
-16.40%
3 Month
-6.23%
6 Month
+35.62%
1 Year
2 Year
5 Year
10 Year
4 years 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 29.72 34.02 39.13 39.10
Return on Capital Employed (%) 37.15 39.27 45.63 46.80
Return on Assets (%) 18.88 22.30 27.50 28.74

Balance Sheet View Details

Particulars 5 years 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03* Rs. Cr.
Shh. Funds 7 10 15 23 57
Non Curr. Liab. 1 2 2 2 2
Curr. Liab. 3 3 4 6 5
Minority Int.
Equity & Liab. 12 15 21 31 64
Non Curr. Assets 4 5 6 7 11
Curr. Assets 7 10 16 24 53
Misc. Exp. not W/O
Total Assets 12 15 21 31 64

Profit Loss View Details

Particulars 4 years 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Net Sales 17 19 23 27
Other Income 1 0 2 2
Total Income 18 20 25 30
Total Expenditure -14 -15 -18 -19
PBIDT 4 4 7 10
Interest 0 0 0 0
Depreciation 0 0 0 0
Taxation -1 -1 -1 -2
Exceptional Items
PAT 2 3 5 7
Adjusted EPS 76 105 176 261

Cash Flow View Details

Particulars 4 years 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 2 3 5 9
Cash Fr. Inv. -1 -1 -1 -2
Cash Fr. Finan. 0 0 0 -1
Net Change 1 2 4 6
Cash & Cash Eqvt 4 6 10 16

Shareholding Pattern View Details

2 Qtrs 2021-09 (%) 2022-03 (%)
Promoter 73.60 73.60
Public 26.40 26.40
Depository Receipts 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00

Announcements View Details

Mon, 23 May 2022
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Pursuant to Regulation 30 and Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 please find attached the transcript of the aforesaid Conference Call held on May 19 2022 at 4 PM.
Fri, 20 May 2022
Intimation Of Audio Recording Of Investor Call For HY2 FY 22 AND FY 22
Pursuant to Regulation 30 and 46 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations 2015 read along with SEBI (Listing Obligation & Disclosure Requirements) (Second Amendment) Regulations 2021 please find audio recording of the Companys Earning Call held with the Investors/ Analysis on May 19 2022 to discuss Audited Financial Results of the Company for the half year and year ended March 31 2022.
Wed, 18 May 2022
Proceedings Of The Board Meeting Held On 17Thmay 2022
Pursuantto the Regulation 30 and 33 read with schedule III of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations 2015 we would like to inform you that the Board of Directors at its meeting held on Tuesday 17thMay 2022 inter-alia approved

1) Audited Financial Results for the Half Yearand Yearended on 31st March 2022along with Statement of Assets and Liabilities and Cash Flow Statement (Copy enclosed).

2) Auditors Report on the Audited Financial Results for the Half Year and Year ended on 31st March 2022 (Copy enclosed).

Technical Scans View Details

Tue, 24 May 2022
Closing Below Previous Low Closing Below Previous Low
High Decrease 1 Month High Decrease 1 Month
High Increase 6 Months High Increase 6 Months
Mon, 23 May 2022
High Delivery Percentage High Delivery Percentage
Opening at High Opening at High

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 219,371.20 914.30 -0.8%
Divi's Laboratories Ltd. 97,215.92 3,662.05 -6.0%
Cipla Ltd. 78,341.65 970.95 +0.0%
Dr. Reddy's Laboratories Ltd. 72,413.55 4,351.10 +1.8%
Apollo Hospitals Enterprise Ltd. 52,337.62 3,640.00 -2.2%
Gland Pharma Ltd. 47,375.00 2,878.60 -3.4%
Torrent Pharmaceuticals Ltd. 44,015.42 2,601.25 -0.6%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 34.04 914.30 -0.8%
Divi's Laboratories Ltd. Consolidated 2022-03 32.84 3,662.05 -6.0%
Cipla Ltd. Consolidated 2022-03 31.13 970.95 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 33.18 4,351.10 +1.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 46.18 3,640.00 -2.2%
Gland Pharma Ltd. Consolidated 2022-03 39.10 2,878.60 -3.4%
Torrent Pharmaceuticals Ltd. Consolidated 2021-12 36.11 2,601.25 -0.6%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 4.25 914.30 -0.8%
Divi's Laboratories Ltd. Consolidated 2022-03 8.29 3,662.05 -6.0%
Cipla Ltd. Consolidated 2022-03 3.76 970.95 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 3.77 4,351.10 +1.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 9.46 3,640.00 -2.2%
Gland Pharma Ltd. Consolidated 2022-03 6.62 2,878.60 -3.4%
Torrent Pharmaceuticals Ltd. Consolidated 2021-12 6.81 2,601.25 -0.6%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 0.08 914.30 -0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 3,662.05 -6.0%
Cipla Ltd. Consolidated 2021-03 0.10 970.95 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,351.10 +1.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 0.62 3,640.00 -2.2%
Gland Pharma Ltd. Consolidated 2021-03 0.00 2,878.60 -3.4%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 0.84 2,601.25 -0.6%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 914.30 -0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 3,662.05 -6.0%
Cipla Ltd. Consolidated 2021-03 14.13 970.95 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,351.10 +1.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,640.00 -2.2%
Gland Pharma Ltd. Consolidated 2021-03 20.97 2,878.60 -3.4%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 23.49 2,601.25 -0.6%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 914.30 -0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 3,662.05 -6.0%
Cipla Ltd. Consolidated 2021-03 14.13 970.95 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,351.10 +1.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,640.00 -2.2%
Gland Pharma Ltd. Consolidated 2021-03 20.97 2,878.60 -3.4%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 23.49 2,601.25 -0.6%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 33,498.14 914.30 -0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 3,662.05 -6.0%
Cipla Ltd. Consolidated 2021-03 19,159.59 970.95 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,351.10 +1.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 10,560.00 3,640.00 -2.2%
Gland Pharma Ltd. Consolidated 2021-03 3,462.88 2,878.60 -3.4%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 8,004.83 2,601.25 -0.6%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 2,284.68 914.30 -0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 3,662.05 -6.0%
Cipla Ltd. Consolidated 2021-03 2,401.30 970.95 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,351.10 +1.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 136.00 3,640.00 -2.2%
Gland Pharma Ltd. Consolidated 2021-03 996.96 2,878.60 -3.4%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 1,251.88 2,601.25 -0.6%